Milestone Scientific Faces Critical Test with 2025 Earnings Report

ROSELAND, N.J. – March 26, 2026 – Milestone Scientific Inc. is gearing up for a pivotal moment as it prepares to host its fourth-quarter and full-year 2025 financial results conference call on April 1, 2026. For the medical technology firm, listed on the NYSE as MLSS, this call is more than a routine financial disclosure; it represents a critical juncture where its new leadership must demonstrate tangible progress in its strategic turnaround and justify its vision for its proprietary computerized drug delivery systems.

Investors, analysts, and industry observers will be closely watching for insights into the company’s financial health and strategic direction. The announcement promises not only a review of the numbers but also a crucial 'business update' that could shed light on product developments, market expansion, and the overall trajectory of a company navigating the competitive MedTech landscape.

A Financial Reckoning

Heading into the announcement, Milestone Scientific’s recent financial performance presents a mixed but cautiously optimistic picture. While the full-year 2025 results are yet to be revealed, the company's third-quarter 2025 report provides essential context. For the period ending September 30, 2025, the company reported revenues of approximately $2.4 million, a slight dip from the prior year, attributed mainly to a slowdown in domestic dental sales. However, this was partially offset by growth in international dental markets and recurring revenue from its medical segment.

More importantly, the company demonstrated significant operational discipline. Its operating loss improved by 23% year-over-year to $(1.1) million, and its net loss of $(0.01) per share beat analyst forecasts. This fiscal prudence is critical, especially after Milestone received a non-compliance notice from the NYSE American in October 2025 regarding its stockholders' equity and a history of losses. The company has since committed to a plan to regain compliance, making the upcoming financial report a key indicator of its progress toward that goal.

Analysts will be scrutinizing the full-year revenue figures against projections, which have forecasted annual revenue of around $13 million. Key metrics to watch will be gross margin, which showed strength in previous quarters, and the company's cash position, which stood at $1.3 million at the end of Q3 2025. The ability to manage cash burn while investing in growth initiatives will be a central theme of the investor call.

Beyond the Numbers: Strategy and Innovation

The most anticipated part of the conference call may be the business update, which will offer a window into the strategic overhaul led by new CEO Eric Hines. Since taking the helm, Hines has emphasized a multi-pronged approach focused on operational efficiency and targeted growth. This includes broad-based expense reductions, a strategic relaunch of the CompuFlo® Epidural System, and a renewed push in the dental market with The Wand® Single Tooth Anesthesia (STA) System.

One key initiative has been the launch of advisor and ambassador programs. The CompuFlo® Advisor Program aims to accelerate commercial adoption in key Medicare jurisdictions, while The Wand® Ambassador Program leverages peer-to-peer engagement to drive market penetration in dentistry. Success in these programs could translate directly into increased utilization and revenue, a point management will likely highlight.

Further fueling speculation about the company's future plans was a recent decision, approved by stockholders, to increase its authorized common stock from 100 million to 125 million shares. While this doesn't mean an immediate issuance of new shares, it provides the company with greater flexibility for potential future fundraising or strategic transactions. The leadership's commentary on this move will be closely analyzed for clues about its long-term capital strategy.

At the heart of Milestone’s value proposition is its proprietary DPS Dynamic Pressure Sensing Technology®. This platform, which enables the objective, real-time measurement of pressure at the needle tip, is the foundation for its products. It is designed to make injections safer, more precise, and more comfortable for patients. Any updates on new applications, patent filings, or enhancements to this core technology will be vital for assessing the company's long-term competitive advantage.

Navigating a Competitive Market

Milestone Scientific operates as a small-cap innovator within vast and growing markets. The global dental anesthesia delivery systems market, valued at over $600 million in 2023, is projected to nearly double by 2032, driven by a demand for painless and minimally invasive procedures. Similarly, the broader injectable drug delivery market is a multi-hundred-billion-dollar industry expanding rapidly with the rise of chronic diseases and biologic drugs.

Within this landscape, Milestone faces competition from a range of medical equipment companies, including Neuronetics, Solana, and Lakeland Industries. The company's strategy hinges on carving out a niche with its technologically superior solutions. Its success depends on its ability to effectively communicate the clinical and economic benefits of its DPS technology to healthcare providers and navigate complex reimbursement pathways.

Analyst sentiment, though limited, remains cautiously bullish. Some analysts have issued "Speculative Buy" ratings with price targets suggesting significant upside from the stock's recent trading levels. This optimism is predicated on the company's ability to execute its strategic shift, particularly in driving sales growth from the medical segment through expanded Medicare coverage for the CompuFlo procedure and boosting its direct-to-consumer dental sales online. The upcoming call will serve as a crucial test of this bull thesis, providing the data and narrative needed to either reinforce or challenge the market's confidence in Milestone's path forward.